Celgene, Acceleron planning submissions for luspatercept

Celgene Corp. (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) said luspatercept (ACE-536) met the primary endpoint in the Phase III MEDALIST trial to treat myelodysplastic syndrome

Read the full 254 word article

User Sign In